Is Cerebras Stock a Buy on the Dip as Revenue Surges?

Cerebras (CBRS) reported Q1 revenue up 92% YoY to $193.4M and narrowed its net loss to $14M (adjusted loss $3.5M), but investors were pressured by guidance that gross margins would fall to 38%-41% for 2026 (from 46.5% in Q1). The company projects full-year 2026 core revenue of $855M-$865M (~69% growth) and Q2 revenue of ~$194M (+88%), supported by a $20B multi-year OpenAI deal and an AWS collaboration combining Trainium with its CS-3 system. While the partnerships could scale faster as cloud deployments ramp, the article frames the setup as highly speculative given a ~$40B market cap vs < $900M projected revenue.

Analysis

The main market error is treating this as a revenue story when it is really a quality-of-earnings story. For a hardware-heavy AI supplier, a temporary gross-margin reset matters because it changes the implied terminal multiple: if the business scales on sub-40% margins, every incremental dollar of revenue is worth far less than investors assume. That makes CBRS vulnerable to multiple compression even if top-line momentum stays intact.

The second-order winner is not necessarily CBRS, but the broader AI infrastructure stack. AWS benefits from optionality by multi-sourcing compute and packaging itself as the control point; if the partnership scales, it validates demand for inference capacity without requiring customers to bet on one vendor. NVDA is still the cleaner way to own the category because the market is paying for platform economics, not for a niche system integrator with high execution risk.

The near-term catalyst path is binary over the next 1-3 months: if management can show the margin dip was one-off and Q2/2H ramp converts into operating leverage, the stock can rebound sharply because the narrative remains under-owned. If margins stay pressured into the next print or guidance gets massaged again, the stock likely de-rates faster than the revenue growth can offset it. The 6-18 month risk is that the business remains capital-intensive and customer-concentrated, which keeps valuation anchored below other AI winners.

Consensus is probably missing that "speculative but promising" can still mean overvalued. The upside case requires not just growth, but proof that scale does not destroy economics; until that is visible, this is a trading vehicle, not a compounding franchise.

Key Decisions for Investors

• Do not chase CBRS weakness; wait for at least one post-earnings bounce before considering entry, and only if management reaffirms that gross margin returns above 40% within 1-2 quarters.
• Preferred relative-value expression: short CBRS / long NVDA on a 1-3 month horizon. The thesis is that NVDA retains premium multiple support while CBRS is still proving it can scale profitably; stop if CBRS reclaims recent post-earnings highs on improving margins.
• If borrow/liquidity is poor, use a defined-risk CBRS put spread into the next catalyst window. Risk/reward improves if the stock fails to regain its IPO reference area and management does not provide clearer 2H margin bridge.
• Long AMZN as the cleaner indirect beneficiary if AWS becomes the orchestration layer for multi-vendor AI infrastructure. This is a lower-beta way to own any validation of the inference market without single-name execution risk.
• Set a hard alert on CBRS gross margin: any sustained print or guide below 40% is a thesis break and should trigger de-risking; a move back above 45% would be the first sign the market has over-penalized the stock.